211 related articles for article (PubMed ID: 7752148)
21. Direct quantification of the rupture force of single hyaluronan/hyaluronan binding protein bonds.
Liu X; Sun JQ; Heggeness MH; Yeh ML; Luo ZP
FEBS Lett; 2004 Apr; 563(1-3):23-7. PubMed ID: 15063717
[TBL] [Abstract][Full Text] [Related]
22. Topographic variation in biglycan and decorin synthesis by articular cartilage in the early stages of osteoarthritis: an experimental study in sheep.
Little CB; Ghosh P; Bellenger CR
J Orthop Res; 1996 May; 14(3):433-44. PubMed ID: 8676257
[TBL] [Abstract][Full Text] [Related]
23. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1).
Dahlberg L; Billinghurst RC; Manner P; Nelson F; Webb G; Ionescu M; Reiner A; Tanzer M; Zukor D; Chen J; van Wart HE; Poole AR
Arthritis Rheum; 2000 Mar; 43(3):673-82. PubMed ID: 10728762
[TBL] [Abstract][Full Text] [Related]
24. Monoclonal antibodies that specifically recognize neoepitope sequences generated by 'aggrecanase' and matrix metalloproteinase cleavage of aggrecan: application to catabolism in situ and in vitro.
Hughes CE; Caterson B; Fosang AJ; Roughley PJ; Mort JS
Biochem J; 1995 Feb; 305 ( Pt 3)(Pt 3):799-804. PubMed ID: 7531436
[TBL] [Abstract][Full Text] [Related]
25. Cleavage of aggrecan at the Asn341-Phe342 site coincides with the initiation of collagen damage in murine antigen-induced arthritis: a pivotal role for stromelysin 1 in matrix metalloproteinase activity.
van Meurs J; van Lent P; Stoop R; Holthuysen A; Singer I; Bayne E; Mudgett J; Poole R; Billinghurst C; van der Kraan P; Buma P; van den Berg W
Arthritis Rheum; 1999 Oct; 42(10):2074-84. PubMed ID: 10524678
[TBL] [Abstract][Full Text] [Related]
26. Mutations in the interglobular domain of aggrecan alter matrix metalloproteinase and aggrecanase cleavage patterns. Evidence that matrix metalloproteinase cleavage interferes with aggrecanase activity.
Mercuri FA; Maciewicz RA; Tart J; Last K; Fosang AJ
J Biol Chem; 2000 Oct; 275(42):33038-45. PubMed ID: 11032846
[TBL] [Abstract][Full Text] [Related]
27. Variations in aggrecan structure modulate its susceptibility to aggrecanases.
Roughley PJ; Barnett J; Zuo F; Mort JS
Biochem J; 2003 Oct; 375(Pt 1):183-9. PubMed ID: 12859252
[TBL] [Abstract][Full Text] [Related]
28. Sites of aggrecan cleavage by recombinant human aggrecanase-1 (ADAMTS-4).
Tortorella MD; Pratta M; Liu RQ; Austin J; Ross OH; Abbaszade I; Burn T; Arner E
J Biol Chem; 2000 Jun; 275(24):18566-73. PubMed ID: 10751421
[TBL] [Abstract][Full Text] [Related]
29. Quantification of a matrix metalloproteinase-generated aggrecan G1 fragment using monospecific anti-peptide serum.
Lark MW; Williams H; Hoernner LA; Weidner J; Ayala JM; Harper CF; Christen A; Olszewski J; Konteatis Z; Webber R
Biochem J; 1995 Apr; 307 ( Pt 1)(Pt 1):245-52. PubMed ID: 7717983
[TBL] [Abstract][Full Text] [Related]
30. Aggrecan degradation in human intervertebral disc and articular cartilage.
Sztrolovics R; Alini M; Roughley PJ; Mort JS
Biochem J; 1997 Aug; 326 ( Pt 1)(Pt 1):235-41. PubMed ID: 9337874
[TBL] [Abstract][Full Text] [Related]
31. Matrix metalloproteinases are involved in C-terminal and interglobular domain processing of cartilage aggrecan in late stage cartilage degradation.
Little CB; Hughes CE; Curtis CL; Janusz MJ; Bohne R; Wang-Weigand S; Taiwo YO; Mitchell PG; Otterness IG; Flannery CR; Caterson B
Matrix Biol; 2002 Apr; 21(3):271-88. PubMed ID: 12009333
[TBL] [Abstract][Full Text] [Related]
32. Membrane type 1 matrix metalloproteinase (MT1-MMP) cleaves the recombinant aggrecan substrate rAgg1mut at the 'aggrecanase' and the MMP sites. Characterization of MT1-MMP catabolic activities on the interglobular domain of aggrecan.
Büttner FH; Hughes CE; Margerie D; Lichte A; Tschesche H; Caterson B; Bartnik E
Biochem J; 1998 Jul; 333 ( Pt 1)(Pt 1):159-65. PubMed ID: 9639575
[TBL] [Abstract][Full Text] [Related]
33. Fibroblast and neutrophil collagenases cleave at two sites in the cartilage aggrecan interglobular domain.
Fosang AJ; Last K; Knäuper V; Neame PJ; Murphy G; Hardingham TE; Tschesche H; Hamilton JA
Biochem J; 1993 Oct; 295 ( Pt 1)(Pt 1):273-6. PubMed ID: 8216228
[TBL] [Abstract][Full Text] [Related]
34. Recombinant human aggrecan G1-G2 exhibits native binding properties and substrate specificity for matrix metalloproteinases and aggrecanase.
Mercuri FA; Doege KJ; Arner EC; Pratta MA; Last K; Fosang AJ
J Biol Chem; 1999 Nov; 274(45):32387-95. PubMed ID: 10542281
[TBL] [Abstract][Full Text] [Related]
35. cDNA cloning and the identification of an aggrecanase-like cleavage site in rat brevican.
Yamada H; Watanabe K; Shimonaka M; Yamasaki M; Yamaguchi Y
Biochem Biophys Res Commun; 1995 Nov; 216(3):957-63. PubMed ID: 7488217
[TBL] [Abstract][Full Text] [Related]
36. Release of hyaluronan and hyaladherins (aggrecan G1 domain and link proteins) from articular cartilage exposed to ADAMTS-4 (aggrecanase 1) or ADAMTS-5 (aggrecanase 2).
Chockalingam PS; Zeng W; Morris EA; Flannery CR
Arthritis Rheum; 2004 Sep; 50(9):2839-48. PubMed ID: 15457452
[TBL] [Abstract][Full Text] [Related]
37. The structure of aggrecan fragments in human synovial fluid. Evidence for the involvement in osteoarthritis of a novel proteinase which cleaves the Glu 373-Ala 374 bond of the interglobular domain.
Sandy JD; Flannery CR; Neame PJ; Lohmander LS
J Clin Invest; 1992 May; 89(5):1512-6. PubMed ID: 1569188
[TBL] [Abstract][Full Text] [Related]
38. Age-related changes in the content of the C-terminal region of aggrecan in human articular cartilage.
Dudhia J; Davidson CM; Wells TM; Vynios DH; Hardingham TE; Bayliss MT
Biochem J; 1996 Feb; 313 ( Pt 3)(Pt 3):933-40. PubMed ID: 8611178
[TBL] [Abstract][Full Text] [Related]
39. Catabolism of aggrecan in cartilage explants. Identification of a major cleavage site within the interglobular domain.
Sandy JD; Neame PJ; Boynton RE; Flannery CR
J Biol Chem; 1991 May; 266(14):8683-5. PubMed ID: 2026585
[TBL] [Abstract][Full Text] [Related]
40. Analysis of aggrecan in human knee cartilage and synovial fluid indicates that aggrecanase (ADAMTS) activity is responsible for the catabolic turnover and loss of whole aggrecan whereas other protease activity is required for C-terminal processing in vivo.
Sandy JD; Verscharen C
Biochem J; 2001 Sep; 358(Pt 3):615-26. PubMed ID: 11535123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
